These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 39034817)

  • 1. Prevalence and prognosis of patients with MASLD-related cirrhosis after an ICU hospitalization in France: A single-centre prospective study.
    Sultanik P; Lherault G; Bouzbib C; Ratziu V; Pais R; Mouri S; Thabut D; Rudler M
    Aliment Pharmacol Ther; 2024 Sep; 60(6):796-810. PubMed ID: 39034817
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validation of the new nomenclature of steatotic liver disease in patients with a history of excessive alcohol intake: an analysis of data from a prospective cohort study.
    Israelsen M; Torp N; Johansen S; Hansen CD; Hansen ED; Thorhauge K; Hansen JK; Villesen I; Bech K; Wernberg C; Andersen P; Lindvig KP; Tsochatzis EA; Thiele M; Rinella ME; Krag A;
    Lancet Gastroenterol Hepatol; 2024 Mar; 9(3):218-228. PubMed ID: 38218202
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Steatotic liver disease predicts cardiovascular disease and advanced liver fibrosis: A community-dwelling cohort study with 20-year follow-up.
    Choe HJ; Moon JH; Kim W; Koo BK; Cho NH
    Metabolism; 2024 Apr; 153():155800. PubMed ID: 38266957
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatotic Liver Disease with Increased Alcohol Intake Increase the Risk of Developing Hepatocellular Carcinoma and Incident or Decompensated Cirrhosis: A Korean Nationwide Study.
    Kim GA; Jeong S; Jang H; Lee DH; Joo SK; Kim W
    Liver Cancer; 2024 Aug; 13(4):426-437. PubMed ID: 39114758
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic dysfunction-associated steatotic liver disease related cirrhosis and incidence of portal vein thrombosis.
    Amjad W; Jiang ZG; Lai M
    Eur J Gastroenterol Hepatol; 2024 Aug; 36(8):1038-1045. PubMed ID: 38829950
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Misclassified Alcohol-related Liver Disease is Common in Presumed Metabolic Dysfunction-associated Steatotic Liver Disease and Highly Increases Risk for Future Cirrhosis.
    Nasr P; Wester A; Ekstedt M; Strandberg R; Kechagias S; Shang Y; Widman L; Hagström H
    Clin Gastroenterol Hepatol; 2024 May; 22(5):1048-1057.e2. PubMed ID: 38237695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence, distribution, and hepatic fibrosis burden of the different subtypes of steatotic liver disease in primary care settings.
    Lee CM; Yoon EL; Kim M; Kang BK; Cho S; Nah EH; Jun DW
    Hepatology; 2024 Jun; 79(6):1393-1400. PubMed ID: 38100294
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term clinical outcomes in steatotic liver disease and incidence of liver-related events, cardiovascular events and all-cause mortality.
    Tamaki N; Kimura T; Wakabayashi SI; Umemura T; Kurosaki M; Loomba R; Izumi N
    Aliment Pharmacol Ther; 2024 Jul; 60(1):61-69. PubMed ID: 38664876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characteristics and long-term mortality of individuals with MASLD, MetALD, and ALD, and the utility of SAFE score.
    Sripongpun P; Kaewdech A; Udompap P; Kim WR
    JHEP Rep; 2024 Oct; 6(10):101127. PubMed ID: 39290401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of steatotic liver disease, MASLD, MetALD and significant fibrosis in people with HIV in the United States.
    Gawrieh S; Vilar-Gomez E; Woreta TA; Lake JE; Wilson LA; Price JC; Naggie S; Sterling RK; Heath S; Corey KE; Cachay ER; Ajmera V; Tonascia J; Sulkowski MS; Chalasani N; Loomba R
    Aliment Pharmacol Ther; 2024 Mar; 59(5):666-679. PubMed ID: 38158589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Racial and ethnic differences and the role of unfavorable social determinants of health across steatotic liver disease subtypes in the United States.
    Ochoa-Allemant P; Marrero JA; Serper M
    Hepatol Commun; 2023 Dec; 7(12):. PubMed ID: 38051551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Physical Activity on Overall Survival and Liver Cirrhosis Incidence in Steatotic Liver Disease: Insights from a Large Cohort Study Using Inverse Probability of Treatment Weighting.
    Yang K; Chung BS; Ryu T
    Nutrients; 2024 Aug; 16(15):. PubMed ID: 39125411
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ALT levels, alcohol use, and metabolic risk factors have prognostic relevance for liver-related outcomes in the general population.
    Männistö V; Salomaa V; Jula A; Lundqvist A; Männistö S; Perola M; Åberg F
    JHEP Rep; 2024 Oct; 6(10):101172. PubMed ID: 39430577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extent to which weight loss contributes to improving metabolic dysfunction-associated and metabolic and alcohol related/associated steatotic liver disease: a study on Japanese participants undergoing health checkups.
    Fukuda T; Okamoto T; Fukaishi T; Kawakami A; Tanaka M; Yamada T; Monzen K
    Front Endocrinol (Lausanne); 2024; 15():1392280. PubMed ID: 38779448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liver Cancer Risk Across Metabolic Dysfunction-Associated Steatotic Liver Disease and/or Alcohol: A Nationwide Study.
    Yun B; Park H; Ahn SH; Oh J; Kim BK; Yoon JH
    Am J Gastroenterol; 2024 Jun; ():. PubMed ID: 38934496
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic Dysfunction-Associated Steatotic Liver Disease and All-Cause and Cause-Specific Mortality.
    Oh R; Kim S; Cho SH; Kim J; Lee YB; Jin SM; Hur KY; Kim G; Kim JH
    Diabetes Metab J; 2024 Aug; ():. PubMed ID: 39197834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of at-risk MASH, MetALD and alcohol-associated steatotic liver disease in the general population.
    Schneider CV; Schneider KM; Raptis A; Huang H; Trautwein C; Loomba R
    Aliment Pharmacol Ther; 2024 May; 59(10):1271-1281. PubMed ID: 38500443
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The prevalence and predictors of metabolic dysfunction-associated steatotic liver disease and fibrosis/cirrhosis among adolescents/young adults.
    Perumpail BJ; Manikat R; Wijarnpreecha K; Cholankeril G; Ahmed A; Kim D
    J Pediatr Gastroenterol Nutr; 2024 Jul; 79(1):110-118. PubMed ID: 38623942
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD)-related advanced fibrosis and cirrhosis in the United States population utilizing AGILE 3 + and AGILE 4 scores: analysis of the NHANES 2017-2018 cycle.
    Alkhouri N; Almomani A; Le P; Payne JY; Asaad I; Polanco P; Leff P; Kumar P; Noureddin M
    BMC Gastroenterol; 2024 Jul; 24(1):218. PubMed ID: 38977950
    [TBL] [Abstract][Full Text] [Related]  

  • 20. National prevalence estimates for steatotic liver disease and subclassifications using consensus nomenclature.
    Lee BP; Dodge JL; Terrault NA
    Hepatology; 2024 Mar; 79(3):666-673. PubMed ID: 37732946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.